Broderick Brian C Cuts Stake in Eli Lilly and Company (LLY)
Broderick Brian C cut its position in Eli Lilly and Company (NYSE:LLY) by 3.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,889 shares of the company’s stock after selling 300 shares during the period. Broderick Brian C’s holdings in Eli Lilly and were worth $732,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of LLY. First Command Financial Services Inc. increased its position in Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares during the period. Heritage Trust Co purchased a new position in Eli Lilly and during the first quarter worth approximately $135,000. Point72 Asia Hong Kong Ltd increased its position in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares during the period. Penserra Capital Management LLC increased its position in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares during the period. Finally, American National Bank increased its position in Eli Lilly and by 5.2% in the second quarter. American National Bank now owns 2,088 shares of the company’s stock worth $172,000 after buying an additional 104 shares during the period. Institutional investors and hedge funds own 75.61% of the company’s stock.
Eli Lilly and Company (NYSE:LLY) traded down 0.47% during midday trading on Friday, hitting $81.15. The stock had a trading volume of 2,446,392 shares. The stock’s 50 day moving average price is $82.91 and its 200-day moving average price is $81.72. The company has a market cap of $85.61 billion, a PE ratio of 35.11 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same period in the prior year, the business earned $0.86 earnings per share. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. Equities research analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. Eli Lilly and’s payout ratio is 90.04%.
COPYRIGHT VIOLATION WARNING: “Broderick Brian C Cuts Stake in Eli Lilly and Company (LLY)” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://theolympiareport.com/2017/08/12/broderick-brian-c-cuts-stake-in-eli-lilly-and-company-lly.html.
A number of equities analysts recently commented on the company. Berenberg Bank reiterated a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. BMO Capital Markets reiterated a “sell” rating and issued a $73.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 price target for the company. in a research note on Wednesday, July 26th. Finally, Leerink Swann downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $93.00 to $90.00 in a research note on Wednesday, July 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. Eli Lilly and currently has a consensus rating of “Hold” and an average target price of $88.27.
In other news, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the transaction, the insider now directly owns 14,041 shares in the company, valued at $1,134,231.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. Insiders have sold 669,733 shares of company stock worth $55,845,287 over the last quarter. 0.20% of the stock is owned by company insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.